CytoReason

CytoReason, a leader and pioneer in computational disease modeling, announced an expansion of its collaboration with Sanofi. The multiyear…

Advanced insights from CytoReason’s disease models will support Pfizer’s drug development process CytoReason announced an extension of its multi-year…

This is your AI Daily Roundup today. We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in …

CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced the signing of a commercial…

CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced the extension of its…

Using its proprietary computational disease models, CytoReason will help Merck understand the drug’s mechanism of action, identify patient populations…

CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals…

The Focus of the Project Is to Tackle Asthma, a Major Chronic Condition Affecting More Than 340 Million People Globally CytoReason, an AI…

Groundbreaking Model Translates the Results of New Mouse Experiments into the Equivalent Human Condition, Outperforming Traditional Methods of…